

Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer
- Oncofertility has been an overlooked standard of care—now states are taking action
- Shane Jacobson talks about his to-do list for ACS
Boost research, forge closer ties with cancer centers, launch an all-out campaign for resources - GLP-1 drugs linked to dramatically lower death rates in colon cancer patients













